Waxman/Hatch Debate Moves Forward: CHPA Aims To Protect OTC Exclusivity

Preservation of the three-year exclusivity awarded for clinical studies supporting Rx-to-OTC switches under the existing Waxman/Hatch Act is the Consumer Healthcare Products Association's top priority as patent reform discussions take shape on Capitol Hill.